Procedural Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions Via the Radial Approach: Insights From an International Chronic Total Occlusion Registry.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
25 02 2019
Historique:
received: 12 09 2018
revised: 25 10 2018
accepted: 15 11 2018
entrez: 21 2 2019
pubmed: 21 2 2019
medline: 26 3 2020
Statut: ppublish

Résumé

This study examined the frequency and outcomes of radial access for chronic total occlusion (CTO) percutaneous coronary intervention (PCI). Radial access improves the safety of PCI, but its role in CTO PCI remains controversial. We compared the clinical, angiographic, and procedural characteristics of 3,790 CTO interventions performed between 2012 and 2018 via radial-only access (RA) (n = 747) radial-femoral access (RFA) (n = 844) and femoral-only access (n = 2,199) access at 23 centers in the United States, Europe, and Russia. Patients' mean age was 65 ± 10 years, and 85% were men. Transradial access (RA and RFA) was used in 42% of CTO interventions and significantly increased over time from 11% in 2012 to 67% in 2018 (p < 0.001). RA patients were younger (age 62 ± 10 years vs. 64 ± 10 years and 65 ± 10 years; p < 0.001), less likely to have undergone prior coronary artery bypass graft surgery (18% vs. 39% and 35%; p < 0.001), and less likely to have undergone prior PCI (60% vs. 63% and 66%; p = 0.005) compared with those who underwent RFA and femoral-only access PCI. RA CTO PCI lesions had lower J-CTO (Multicenter CTO Registry in Japan) (2.1 ± 1.4 vs. 2.6 ± 1.3 and 2.5 ± 1.3; p < 0.001) and PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) complication (2.3 ± 1.9 vs. 3.2 ± 2.0 and 3.2 ± 1.9; p < 0.001) scores. The mean sheath size was significantly smaller in the RA group (6.6 ± 0.7 vs. 7.0 ± 0.6 and 7.3 ± 0.8; p < 0.0001), although it increased with lesion complexity. Antegrade dissection re-entry (20% vs. 33% and 32%; p < 0.001) was less commonly used with RA, whereas use of retrograde techniques was highest with RFA (47%). The overall rates of technical success (89% vs. 88% vs. 86%; p = 0.061), procedural success (86% vs. 85% vs. 85%; p = 0.528), and in-hospital major complication (2.47% vs. 3.40% vs. 2.18%; p = 0.830) were similar in all 3 groups, whereas major bleeding was lower in the RA group (0.55% vs. 1.94% and 0.88%; p = 0.013). Transradial access is increasingly being used for CTO PCI and is associated with similar technical and procedural success and lower major bleeding rates compared with femoral-only access interventions. (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention [PROGRESS CTO]; NCT02061436).

Sections du résumé

OBJECTIVES
This study examined the frequency and outcomes of radial access for chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
BACKGROUND
Radial access improves the safety of PCI, but its role in CTO PCI remains controversial.
METHODS
We compared the clinical, angiographic, and procedural characteristics of 3,790 CTO interventions performed between 2012 and 2018 via radial-only access (RA) (n = 747) radial-femoral access (RFA) (n = 844) and femoral-only access (n = 2,199) access at 23 centers in the United States, Europe, and Russia.
RESULTS
Patients' mean age was 65 ± 10 years, and 85% were men. Transradial access (RA and RFA) was used in 42% of CTO interventions and significantly increased over time from 11% in 2012 to 67% in 2018 (p < 0.001). RA patients were younger (age 62 ± 10 years vs. 64 ± 10 years and 65 ± 10 years; p < 0.001), less likely to have undergone prior coronary artery bypass graft surgery (18% vs. 39% and 35%; p < 0.001), and less likely to have undergone prior PCI (60% vs. 63% and 66%; p = 0.005) compared with those who underwent RFA and femoral-only access PCI. RA CTO PCI lesions had lower J-CTO (Multicenter CTO Registry in Japan) (2.1 ± 1.4 vs. 2.6 ± 1.3 and 2.5 ± 1.3; p < 0.001) and PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) complication (2.3 ± 1.9 vs. 3.2 ± 2.0 and 3.2 ± 1.9; p < 0.001) scores. The mean sheath size was significantly smaller in the RA group (6.6 ± 0.7 vs. 7.0 ± 0.6 and 7.3 ± 0.8; p < 0.0001), although it increased with lesion complexity. Antegrade dissection re-entry (20% vs. 33% and 32%; p < 0.001) was less commonly used with RA, whereas use of retrograde techniques was highest with RFA (47%). The overall rates of technical success (89% vs. 88% vs. 86%; p = 0.061), procedural success (86% vs. 85% vs. 85%; p = 0.528), and in-hospital major complication (2.47% vs. 3.40% vs. 2.18%; p = 0.830) were similar in all 3 groups, whereas major bleeding was lower in the RA group (0.55% vs. 1.94% and 0.88%; p = 0.013).
CONCLUSIONS
Transradial access is increasingly being used for CTO PCI and is associated with similar technical and procedural success and lower major bleeding rates compared with femoral-only access interventions. (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention [PROGRESS CTO]; NCT02061436).

Identifiants

pubmed: 30784639
pii: S1936-8798(18)32309-4
doi: 10.1016/j.jcin.2018.11.019
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02061436']

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

346-358

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL118138
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Peter Tajti (P)

Minneapolis Heart Institute and the Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota; University of Szeged, Division of Invasive Cardiology, Second Department of Internal Medicine and Cardiology Center, Szeged, Hungary.

Khaldoon Alaswad (K)

Henry Ford Hospital, Detroit, Michigan.

Dimitri Karmpaliotis (D)

Columbia University, New York, New York.

Farouc A Jaffer (FA)

Massachusetts General Hospital, Boston, Massachusetts.

Robert W Yeh (RW)

Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Mitul Patel (M)

VA San Diego Healthcare System and University of California, San Diego, La Jolla, California.

Ehtisham Mahmud (E)

VA San Diego Healthcare System and University of California, San Diego, La Jolla, California.

James W Choi (JW)

Baylor Heart and Vascular Hospital, Dallas, Texas.

M Nicholas Burke (MN)

Minneapolis Heart Institute and the Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota.

Anthony H Doing (AH)

Medical Center of the Rockies, Loveland, Colorado.

Phil Dattilo (P)

Medical Center of the Rockies, Loveland, Colorado.

Catalin Toma (C)

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

A J Conrad Smith (AJC)

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Barry F Uretsky (BF)

VA Central Arkansas Healthcare System, Little Rock, Arkansas.

Elizabeth Holper (E)

The Heart Hospital Baylor Plano, Plano, Texas.

Srinivasa Potluri (S)

The Heart Hospital Baylor Plano, Plano, Texas.

R Michael Wyman (RM)

Torrance Memorial Medical Center, Torrance, California.

David E Kandzari (DE)

Piedmont Heart Institute, Atlanta, Georgia.

Santiago Garcia (S)

VA Minneapolis Healthcare System and University of Minnesota, Minneapolis, Minnesota.

Oleg Krestyaninov (O)

Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health of Russian Federation, Novosibirsk, Russian Federation.

Dmitrii Khelimskii (D)

Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health of Russian Federation, Novosibirsk, Russian Federation.

Michalis Koutouzis (M)

Korgialeneio-Benakeio Hellenic Red Cross General Hospital of Athens, Athens, Greece.

Ioannis Tsiafoutis (I)

Korgialeneio-Benakeio Hellenic Red Cross General Hospital of Athens, Athens, Greece.

Jaikirshan J Khatri (JJ)

Cleveland Clinic, Cleveland, Ohio.

Wissam Jaber (W)

Emory University, Atlanta, Georgia.

Habib Samady (H)

Emory University, Atlanta, Georgia.

Brian Jefferson (B)

Tristar Centennial Medical Center, Nashville, Tennessee.

Taral Patel (T)

Tristar Centennial Medical Center, Nashville, Tennessee.

Shuaib Abdullah (S)

VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.

Jeffrey W Moses (JW)

Columbia University, New York, New York.

Nicholas J Lembo (NJ)

Columbia University, New York, New York.

Manish Parikh (M)

Columbia University, New York, New York.

Ajay J Kirtane (AJ)

Columbia University, New York, New York.

Ziad A Ali (ZA)

Columbia University, New York, New York.

Darshan Doshi (D)

Columbia University, New York, New York.

Iosif Xenogiannis (I)

Minneapolis Heart Institute and the Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota.

Larissa I Stanberry (LI)

Minneapolis Heart Institute and the Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota.

Bavana V Rangan (BV)

Minneapolis Heart Institute and the Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota.

Imre Ungi (I)

University of Szeged, Division of Invasive Cardiology, Second Department of Internal Medicine and Cardiology Center, Szeged, Hungary.

Subhash Banerjee (S)

VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute and the Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota. Electronic address: esbrilakis@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH